KYMR VS BLTE Stock Comparison

Performance

KYMR
10/100

KYMR returned -38.95% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

BLTE
100/100

BLTE returned 52.13% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Sentiment

KYMR
69/100

KYMR had a bullish sentiment score of 68.98% across Twitter and StockTwits over the last 12 months. It had an average of 2.55 posts, 2.33 comments, and 0.61 likes per day.

BLTE

"Sentiment" not found for BLTE

Technicals

KYMR
75/100

KYMR receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

BLTE
64/100

BLTE receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

KYMR
10/100

KYMR has missed earnings 11 times in the last 20 quarters.

BLTE
10/100

BLTE has missed earnings 4 times in the last 20 quarters.

Profit

KYMR
10/100

Out of the last 17 quarters, KYMR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

BLTE
10/100

Out of the last 13 quarters, BLTE has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

KYMR
47/100

KYMR has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

BLTE
61/100

BLTE has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Kymera Therapeutics, Inc. Common Stock Summary

Nasdaq / KYMR

Healthcare

Biotechnology

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Belite Bio, Inc American Depositary Shares Summary

Nasdaq / BLTE

Healthcare

Biotechnology

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Power up your portfolio